Table 3.
Immediately pre-BMC-Tx | Immediately post-BMC-Tx | 3 months after BMC-Tx | 6 months after BMC-Tx | 12 months after BMC-Tx | |
---|---|---|---|---|---|
Global EF (%) | 46 ± 10 | 53 ± 8a | 52 ± 8a | ||
The size of infarct area (%) | 27 ± 9 | 19 ± 8b | 18 ± 5b | ||
Infarct wall movement velocity (cm/s) | 1.80 ± 0.74 | 2.98 ± 0.89b | 3.45 ± 0.5b | ||
LVEDV (mL) | 138 ± 34 | 139 ± 32c | 138 ± 32c | ||
LVESV (mL) | 75 ± 20 | 65 ± 10a | 66 ± 10a | ||
SVI (mL/m) | 34 ± 10 | 42 ± 9a | 41 ± 8a | ||
CD34/45+ BM-CPCs | 190 ± 50 | 193 ± 50c | 290 ± 110a | 288 ± 100a | 315 ± 90b |
CD133/45+ BM-CPCs | 51 ± 20 | 52 ± 20c | 90 ± 25a | 99 ± 20b | 95 ± 25a |
BNP (pg/mL) | 178 ± 89 | 65 ± 28b | 61 ± 19b | 60 ± 15b | |
NYHA classification | 2.40 ± 0.8 | 1.80 ± 0.8b | 1.7 ± 0.8b | 1.5 ± 0.8b |
P = 0.01–0.001 (compared with baseline).
P < 0.001 (compared with baseline).
P = not significant.